Loading...
XHKG
1681
Market cap1.44bUSD
Jul 09, Last price  
13.42HKD
1D
-1.03%
1Q
-21.15%
Jan 2017
247.67%
IPO
184.32%
Name

Consun Pharmaceutical Group Ltd

Chart & Performance

D1W1MN
XHKG:1681 chart
P/E
9.04
P/S
2.85
EPS
1.28
Div Yield, %
4.69%
Shrs. gr., 5y
0.91%
Rev. gr., 5y
14.29%
Revenues
3.42b
+15.17%
457,801,000571,765,000730,683,000831,108,0001,223,488,0001,660,230,0001,843,973,0001,728,256,0001,752,830,0002,044,660,0002,339,650,0002,590,115,0002,967,235,0003,417,355,000
Net income
1.08b
+18.41%
136,206,000152,882,000211,200,000249,689,000307,526,000396,242,000465,353,00079,820,000498,788,000590,172,000682,907,000784,534,000910,458,0001,078,067,000
CFO
1.21b
+11.48%
128,832,000163,610,000294,721,000184,043,000449,177,000252,123,000754,210,000383,315,000867,058,000725,537,000947,679,000818,973,0001,086,987,0001,211,796,000
Dividend
Jun 09, 20260.4 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Consun Pharmaceutical Group Limited operates as an investment holding company, primarily engaged in the research, development, manufacturing, and distribution of traditional Chinese medicines and sophisticated medical contrast agents throughout the People's Republic of China. The company's operations are structured into two main divisions: Consun Pharmaceutical and Yulin Pharmaceutical. Consun offers a diverse array of pharmaceutical products. For kidney-related conditions, it provides uremic clearance granule for chronic kidney diseases and Yishen Huashi particles to address proteinuria. In the field of medical imaging, the company supplies Gadopentetate Dimeglumine injections, a contrast medium vital for MRI diagnostics of the central nervous system, abdomen, chest, pelvis, and extremities, alongside assessing renal function. Another key imaging agent is Iopamidol injections, utilized in neuroradiology, angiography, and urography. Its extensive portfolio of traditional Chinese medicines includes Zhixueling capsules, effective in managing various bleeding disorders such as uterine bleeding, prolonged lochia, intermenstrual spotting, post-contraceptive ring bleeding, hemorrhoidal bleeding, and epistaxis. Gyn Antidysmenorrheic tablets are offered to alleviate irregular and painful menstruation, including issues experienced during perimenopause due to hepatic depression and blood deficiency. For feminine hygiene, Antibacterial Fujie lotion combats common vaginal infections caused by Staphylococcus aureus, Candida albicans, and Escherichia coli. The company also markets bone-setting liquid and Yunxiang analgesic tincture for a range of ailments including rheumatism, common colds, headaches, stomachaches, chest pain, gastric pain, and chilblains. Additionally, Sanqi Chuangchun capsules are available to enhance blood circulation and reduce stasis, while Shiduqing capsules, tablets, and Paeonol ointment target various skin conditions. The product line is further rounded out with hepatobiliary, gastroenterology, tonic, and other general medicines. Beyond its traditional Chinese remedies and contrast media, the company also markets pharmaceutical products such as Yuanli Kang, an iron-dextrin oral solution; Yibao Yua, an erythromycin estolate suspension; and Yuantong Ning, a cetirizine hydrochloride oral solution. Established in 1997, Consun Pharmaceutical Group Limited is headquartered in Guangzhou, People's Republic of China.
IPO date
Dec 19, 2013
Employees
3,009
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT